{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"11.6","value":"5.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Kaplan-Meier method was used. The log-rank test was performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model was used to include multiple covariates in the time-to-event analysis.","dispersionType":"Full Range","groups":[{"description":"Akt inhibitor MK2206 200 mg orally once a week, repeats every 28 days for up to 12 courses.","id":"OG000","title":"Akt Inhibitor MK2206"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}